Our journey to successful gene therapy for hemophilia B.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Advances in viral vector-based delivery systems for gene therapy: a comprehensive review.3 Biotech · 2025
   Review
2. Current Clinical Applications of In Vivo Gene Therapy with AAVs.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
   Review
3. Gene Therapy Leaves a Vicious Cycle.Frontiers in oncology · 2019
   Review
4. Serotype survey of AAV gene delivery via subconjunctival injection in mice.Gene therapy · 2018
   Article
5. Gene Therapy for Hemophilia.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
   Review
6. Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
   Article
7. Progress and challenges in viral vector manufacturing.Human molecular genetics · 2016
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as